WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same perio ...

At Revvity, "impossible†is inspiration, and "can't be done†is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. WALTHAM, Mass.--(BUSINESS WIRE) ...

Group 1 - Halliburton Company (NYSE:HAL) is recognized for its potential in the oil and gas sector, particularly in the context of rebuilding efforts in regions like Iraq and Venezuela [1] - The stock has seen significant price increases, leading to concerns about overvaluation, as investors may face losses if they entered at high prices [1] - The timeframe for realizing profits from Halliburton's potential is expected to be long-term, spanning years rather than days [1] Group 2 - Halliburton provides essential equipment, technologies, and services for oil and gas exploration, drilling, completion, and production [2] - There is a belief that certain AI stocks may offer better investment opportunities with higher upside potential and lower downside risk compared to Halliburton [3]

Company Overview - Revvity, Inc. (RVTY) is a leading provider of health sciences solutions, technologies, and diagnostic services, headquartered in Waltham, Massachusetts, with a market cap of $10.3 billion [1] Stock Performance - RVTY shares have underperformed the broader market, declining 15% over the past year, while the S&P 500 Index has increased by nearly 12.3% [2] - In 2025, RVTY's stock fell 16.6%, contrasting with the S&P 500's 12.5% rise on a year-to-date basis [2] - Compared to the Health Care Select Sector SPDR Fund (XLV), which gained about 7.5% year-to-date, RVTY's performance has been notably weaker [3] Financial Results - For Q3, RVTY reported revenue of $7 billion, reflecting a year-over-year increase of 2.2%, while adjusted EPS fell 7.8% to $1.18 [4] - Analysts project RVTY's EPS to grow marginally to $4.92 on a diluted basis for the current fiscal year ending in December [4] - RVTY has a strong earnings surprise history, beating consensus estimates in each of the last four quarters [4] Analyst Ratings - Among 17 analysts covering RVTY, the consensus rating is a "Moderate Buy," consisting of nine "Strong Buy" ratings, one "Moderate Buy," and seven "Holds" [5] - Brandon Couillard from Wells Fargo maintained a "Hold" rating with a price target of $102, indicating a potential upside of 9.6% from current levels [6] - The mean price target of $113.07 suggests a 21.5% premium to RVTY's current price, while the highest price target of $135 indicates a potential upside of 45.1% [6]